Velexbru (tirabrutinib hydrochloride) vs Jaypirca (pirtobrutinib)

Velexbru (tirabrutinib hydrochloride) and Jaypirca (pirtobrutinib) are both Bruton's tyrosine kinase (BTK) inhibitors used in the treatment of certain hematological malignancies, but they differ in their specificity and stage of clinical development. Velexbru is known for its high selectivity for BTK, potentially leading to fewer off-target effects, and has been approved in Japan for the treatment of certain B-cell malignancies. Jaypirca, on the other hand, is designed to be a non-covalent BTK inhibitor, which may overcome resistance to other BTK inhibitors, and is currently being evaluated in clinical trials for patients who have previously been treated with other BTK inhibitors. When deciding between these medications, a patient should consider factors such as the specific type of blood cancer they have, prior treatments, the approval status of the medication in their region, and the potential side effect profiles, and should always consult with their healthcare provider to determine the most appropriate treatment option.

Difference between Velexbru and Jaypirca

Metric	Velexbru (tirabrutinib hydrochloride)	Jaypirca (pirtobrutinib)
Generic name	Tirabrutinib hydrochloride	Pirtobrutinib
Indications	Approved for the treatment of various B-cell malignancies, such as mantle cell lymphoma (MCL) in patients who have received at least one prior therapy.	Investigational for the treatment of B-cell malignancies, including chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL), in patients who have received prior therapies.
Mechanism of action	Bruton's tyrosine kinase (BTK) inhibitor	Next-generation, highly selective, non-covalent Bruton's tyrosine kinase (BTK) inhibitor
Brand names	Velexbru	Jaypirca
Administrative route	Oral	Oral
Side effects	Common side effects include diarrhea, fatigue, rash, and infections.	Side effects data are not fully established as the drug is still investigational, but may include diarrhea, fatigue, cytopenias, and infections.
Contraindications	Known hypersensitivity to tirabrutinib or any of its excipients.	Not fully established, but likely to include known hypersensitivity to pirtobrutinib or any of its excipients.
Drug class	BTK inhibitor	BTK inhibitor
Manufacturer	Ono Pharmaceutical Co., Ltd. and Daiichi Sankyo	Loxo Oncology at Lilly

Efficacy

Velexbru (Tirabrutinib Hydrochloride) Efficacy in Lymphoma

Velexbru, known by its generic name tirabrutinib hydrochloride, is a Bruton's tyrosine kinase (BTK) inhibitor that has shown efficacy in the treatment of certain types of lymphoma. Specifically, tirabrutinib has demonstrated promising results in clinical trials for patients with mantle cell lymphoma (MCL) and other B-cell malignancies. In clinical studies, tirabrutinib has been observed to induce a high rate of objective response rates (ORR) in relapsed or refractory MCL patients. The drug works by inhibiting the BTK enzyme, which plays a critical role in the proliferation and survival of malignant B-cells.

Studies have shown that Velexbru can lead to partial or complete responses in a significant proportion of patients. The duration of response varies, with some patients achieving sustained remissions. The efficacy of tirabrutinib in lymphoma is further underscored by its ability to produce responses in patients who have previously been treated with other BTK inhibitors, indicating its potential as a second-line therapy or in cases where patients have developed resistance to first-line treatments.

Jaypirca (Pirtobrutinib) Efficacy in Lymphoma

Jaypirca, with the generic name pirtobrutinib, is another novel BTK inhibitor that has demonstrated efficacy in the treatment of lymphoma, particularly in patients with B-cell malignancies. Pirtobrutinib has been designed to target both wild-type and C481-mutated BTK, which allows it to be effective even in cases where resistance to other BTK inhibitors has developed. Clinical trials have shown that pirtobrutinib can achieve significant ORR in patients with various types of relapsed or refractory non-Hodgkin lymphoma, including those with mantle cell lymphoma, marginal zone lymphoma, and Waldenström's macroglobulinemia.

The efficacy of Jaypirca is highlighted by its ability to induce responses in a patient population with a high unmet medical need, including those who have exhausted other therapeutic options. The drug's unique binding mechanism allows it to remain effective where other BTK inhibitors fail, providing a new line of hope for patients with advanced lymphoma. Ongoing studies continue to evaluate the long-term efficacy and safety profile of pirtobrutinib in a larger cohort of lymphoma patients.

Regulatory Agency Approvals

Velexbru

Pharmaceuticals and Medical Devices Agency (PMDA), Japan

Jaypirca

Food and Drug Administration (FDA), USA

Access Velexbru or Jaypirca today

If Velexbru or Jaypirca are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.

Buy Velexbru

Buy Jaypirca

How it works

Make an enquiry

Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.

Breeze through the paperwork

We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.

Get a personalized quote

We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.

Receive your medicine

Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.

Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.

Let's talk

If you have any questions, call us or send us a message through WhatsApp or email: